000 | 03084nam a22003735i 4500 | ||
---|---|---|---|
001 | 309660 | ||
003 | MX-SnUAN | ||
005 | 20160429160316.0 | ||
007 | cr nn 008mamaa | ||
008 | 150903s2008 sz | o |||| 0|eng d | ||
020 |
_a9783764377243 _99783764377243 |
||
024 | 7 |
_a10.1007/9783764377243 _2doi |
|
035 | _avtls000362821 | ||
039 | 9 |
_a201509031020 _bVLOAD _c201405070334 _dVLOAD _y201402211058 _zstaff |
|
040 |
_aMX-SnUAN _bspa _cMX-SnUAN _erda |
||
050 | 4 | _aRM1-950 | |
100 | 1 |
_aWeinberg, Jeffrey M. _eeditor. _9350061 |
|
245 | 1 | 0 |
_aTreatment of Psoriasis / _cedited by Jeffrey M. Weinberg. |
264 | 1 |
_aBasel : _bBirkhäuser Basel, _c2008. |
|
300 | _brecurso en línea. | ||
336 |
_atexto _btxt _2rdacontent |
||
337 |
_acomputadora _bc _2rdamedia |
||
338 |
_arecurso en línea _bcr _2rdacarrier |
||
347 |
_aarchivo de texto _bPDF _2rda |
||
490 | 0 | _aMilestones in Drug Therapy | |
500 | _aSpringer eBooks | ||
505 | 0 | _aIntroduction: History of psoriasis and psoriasis therapy -- The pathophysiology of psoriasis -- Psoriasis and psoriatic arthritis: a clinical review -- Topical therapy I: corticosteroids and vitamin D analogs -- Topical therapy II: retinoids, immunomodulators, and others -- Ultraviolet and laser therapy -- Traditional systemic therapy I: methotrexate and cyclosporine -- Traditional systemic therapy II: retinoids and others (hydroxyurea, thiopurine antimetabolites, mycophenlic acid, sulfasalazine) -- Biologic therapy for psoriasis: an overview of infliximab, etanercept, adalimumab, efalizumab, and alefacept -- Biologic and oral therapies in development for the treatment of psoriasis -- Quality of life issues in psoriasis. | |
520 | _aPsoriasis is an inherited skin disease that has been diagnosed in 4.5 million adults in the United States. About 10 percent to 30 percent of people with psoriasis also develop psoriatic arthritis, which causes pain, stiffness and swelling in and around the joints. The book reviews the clinical manifestations of these two entities. The main focus is on the evolving paradigm of therapy. Topical and ultraviolet therapy are discussed first, followed by traditional systemic therapy. A major focus is on biologic therapies. New agents in development are also reviewed. The book concludes with an evaluation of the quality of life impact of this disease. This volume provides an in-depth overview of the current state of psoriasis and its management. It is of interest to clinicians, researchers, and even patients who wish to learn more. It is also of interest to those in the pharmaceutical industry, and those in finance who cover the pharmaceutical field. | ||
590 | _aPara consulta fuera de la UANL se requiere clave de acceso remoto. | ||
710 | 2 |
_aSpringerLink (Servicio en línea) _9299170 |
|
776 | 0 | 8 |
_iEdición impresa: _z9783764377229 |
856 | 4 | 0 |
_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-7643-7724-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL) |
942 | _c14 | ||
999 |
_c309660 _d309660 |